BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia.
BARD1 Life Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.10|
|52 Week High||AU$0.57|
|52 Week Low||AU$5.60|
|1 Month Change||-6.41%|
|3 Month Change||-35.40%|
|1 Year Change||40.39%|
|3 Year Change||4.29%|
|5 Year Change||4.29%|
|Change since IPO||52.08%|
Recent News & Updates
|BD1||AU Healthcare||AU Market|
Return vs Industry: BD1 exceeded the Australian Healthcare industry which returned 10.7% over the past year.
Return vs Market: BD1 exceeded the Australian Market which returned 21.1% over the past year.
Stable Share Price: BD1 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BD1's weekly volatility has decreased from 25% to 9% over the past year.
About the Company
BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia. The company offers hTERT test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for ovarian and breast cancers, and research-stage projects for prostate and other cancers.
BARD1 Life Sciences Fundamentals Summary
|BD1 fundamental statistics|
Is BD1 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BD1 income statement (TTM)|
|Cost of Revenue||AU$1.77m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-877.49%|
How did BD1 perform over the long term?See historical performance and comparison
Is BARD1 Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BD1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BD1 is overvalued based on its PB Ratio (3.5x) compared to the AU Healthcare industry average (2.2x).
How is BARD1 Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BARD1 Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has BARD1 Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BD1 is currently unprofitable.
Growing Profit Margin: BD1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BD1 is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.
Accelerating Growth: Unable to compare BD1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BD1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: BD1 has a negative Return on Equity (-38.38%), as it is currently unprofitable.
How is BARD1 Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: BD1's short term assets (A$5.6M) exceed its short term liabilities (A$1.5M).
Long Term Liabilities: BD1's short term assets (A$5.6M) exceed its long term liabilities (A$3.0M).
Debt to Equity History and Analysis
Debt Level: BD1 is debt free.
Reducing Debt: BD1 has no debt compared to 5 years ago when its debt to equity ratio was 2.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BD1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BD1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.7% each year
What is BARD1 Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BD1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BD1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BD1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BD1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BD1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of BARD1 Life Sciences Limited since November 7, 2016. Dr. Hinch is a biotechnology executive and consultant...
CEO Compensation Analysis
Compensation vs Market: Leearne's total compensation ($USD649.51K) is above average for companies of similar size in the Australian market ($USD303.55K).
Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.
Experienced Management: BD1's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: BD1's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.
BARD1 Life Sciences Limited's employee growth, exchange listings and data sources
- Name: BARD1 Life Sciences Limited
- Ticker: BD1
- Exchange: ASX
- Founded: 1983
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$100.669m
- Shares outstanding: 91.93m
- Website: https://www.bard1.com
Number of Employees
- BARD1 Life Sciences Limited
- 23 Normanby Road
- Notting Hill
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:20|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.